Literature DB >> 18424697

Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.

Samik Basu1, Tatiana Golovina, Tatiana Mikheeva, Carl H June, James L Riley.   

Abstract

Addition of rapamycin to cultures of expanding natural CD4+CD25+Foxp3+ T regulatory cells (Tregs) helps maintain their suppressive activity, but the underlying mechanism is unclear. Pim 2 is a serine/threonine kinase that can confer rapamycin resistance. Unexpectedly, pim 2 was found to be constitutively expressed in freshly isolated, resting Tregs, but not in CD4+CD25- T effector cells. Introduction of Foxp3, but not Foxp3Delta2, into effector T cells induced pim 2 expression and conferred preferential expansion in the presence of rapamycin, indicating that Foxp3 can regulate pim 2 expression. Finally, we determined there is a positive correlation between Treg expansion and Foxp3 expression in the presence of rapamycin. Together, these results indicate that Tregs are programmed to be resistant to rapamycin, providing further rationale for why this immunosuppressive drug should be used in conjunction with expanded Tregs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424697      PMCID: PMC2504517          DOI: 10.4049/jimmunol.180.9.5794

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement.

Authors:  J L Riley; P J Blair; J T Musser; R Abe; K Tezuka; T Tsuji; C H June
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

Review 2.  The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines.

Authors:  Eileen White
Journal:  Genes Dev       Date:  2003-08-01       Impact factor: 11.361

Review 3.  Regulatory T-cell therapy: is it ready for the clinic?

Authors:  Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2005-04       Impact factor: 53.106

4.  Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc.

Authors:  J D Allen; E Verhoeven; J Domen; M van der Valk; A Berns
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

5.  Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation.

Authors:  Teija L T Aho; Riikka J Lund; Emmi K Ylikoski; Sampsa Matikainen; Riitta Lahesmaa; Päivi J Koskinen
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

6.  The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.

Authors:  Casey J Fox; Peter S Hammerman; Ryan M Cinalli; Stephen R Master; Lewis A Chodosh; Craig B Thompson
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

7.  Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.

Authors:  Robert Zeiser; Dennis B Leveson-Gower; Elizabeth A Zambricki; Neeraja Kambham; Andreas Beilhack; John Loh; Jing-Zhou Hou; Robert S Negrin
Journal:  Blood       Date:  2007-10-29       Impact factor: 22.113

8.  The Pim kinases control rapamycin-resistant T cell survival and activation.

Authors:  Casey J Fox; Peter S Hammerman; Craig B Thompson
Journal:  J Exp Med       Date:  2005-01-10       Impact factor: 14.307

9.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Manuela Battaglia; Angela Stabilini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

10.  Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2.

Authors:  N M van der Lugt; J Domen; E Verhoeven; K Linders; H van der Gulden; J Allen; A Berns
Journal:  EMBO J       Date:  1995-06-01       Impact factor: 11.598

View more
  79 in total

1.  Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice.

Authors:  Ying Wang; Geoffrey Camirand; Yan Lin; Monica Froicu; Songyan Deng; Warren D Shlomchik; Fadi G Lakkis; David M Rothstein
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

2.  Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.

Authors:  Shoba Amarnath; Francis A Flomerfelt; Carliann M Costanzo; Jason E Foley; Jacopo Mariotti; Daniel M Konecki; Anu Gangopadhyay; Michael Eckhaus; Susan Wong; Bruce L Levine; Carl H June; Daniel H Fowler
Journal:  Autophagy       Date:  2010-05-16       Impact factor: 16.016

3.  Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus.

Authors:  K Singh; N Kozyr; L Stempora; A D Kirk; C P Larsen; B R Blazar; L S Kean
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

4.  Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

Authors:  Shuling Zhang; Julie A Readinger; Wendy DuBois; Mirkka Janka-Junttila; Richard Robinson; Margaret Pruitt; Val Bliskovsky; Julie Z Wu; Kaori Sakakibara; Jyoti Patel; Carole A Parent; Lino Tessarollo; Pamela L Schwartzberg; Beverly A Mock
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

5.  Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Authors:  Moanaro Biswas; Debalina Sarkar; Sandeep R P Kumar; Sushrusha Nayak; Geoffrey L Rogers; David M Markusic; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 6.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells.

Authors:  Samik Basu; Britany Hubbard; Ethan M Shevach
Journal:  J Leukoc Biol       Date:  2014-12-09       Impact factor: 4.962

8.  Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients.

Authors:  Giorgio Raimondi; Tina L Sumpter; Benjamin M Matta; Mahesh Pillai; Natasha Corbitt; Yoram Vodovotz; Zhiliang Wang; Angus W Thomson
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

9.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

Authors:  Dat Q Tran; John Andersson; Donna Hardwick; Lolita Bebris; Gabor G Illei; Ethan M Shevach
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

10.  Ethylenecarbodiimide-coupled allogeneic antigen presenting cells induce human CD4+ regulatory T cells.

Authors:  Michael H Albert; Xue-Zhong Yu; Thomas Magg
Journal:  Clin Immunol       Date:  2008-09-25       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.